

FIGURE 1

2 / 11

FIGURE 2B



SCF IL3





FIGURE 2A



SCF IL3 EPO



BEST AVAILABLE COPY

3 / 11

PV PATIENT




FIGURE 3

BEST AVAILABLE COPY

4 / 11






FIGURE 4

BEST AVAILABLE COPY



**FIGURE 5**

6 / 11




FIGURE 6B




FIGURE 6A




FIGURE 6C

8 / 11




FIGURE 7



9 / 11

sequences for V617F JAK2 of the siRNA #1, 2 and 3

UGGAGUAUGU	UUCUGUGGA	position 11 = siRNA #3
GGAGUAUGU	UUCUGUGGAG	position 10 = siRNA #1
GAGUAUGU	UUCUGUGGAGA	position 9 = siRNA #4



Mutation

**FIGURE 8**




FIGURE 9

11 / 11

Reduced expression of WT JAK2 by  
non-specific JAK2 V617F siRNA  
(positive control)



Jak2

FIGURE 10

BEST AVAILABLE COPY